Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.

Iyer S, Sam FS, DiPrimio N, Preston G, Verheijen J, Murthy K, Parton Z, Tsang H, Lao J, Morava E, Perlstein EO.

Dis Model Mech. 2019 Nov 11;12(11). pii: dmm040584. doi: 10.1242/dmm.040584.

2.

Drug screens of NGLY1 deficiency in worm and fly models reveal catecholamine, NRF2 and anti-inflammatory-pathway activation as potential clinical approaches.

Iyer S, Mast JD, Tsang H, Rodriguez TP, DiPrimio N, Prangley M, Sam FS, Parton Z, Perlstein EO.

Dis Model Mech. 2019 Nov 4;12(11). pii: dmm040576. doi: 10.1242/dmm.040576.

3.

Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation.

Lao JP, DiPrimio N, Prangley M, Sam FS, Mast JD, Perlstein EO.

G3 (Bethesda). 2019 Feb 7;9(2):413-423. doi: 10.1534/g3.118.200934.

4.

A three dimensional micropatterned tumor model for breast cancer cell migration studies.

Peela N, Sam FS, Christenson W, Truong D, Watson AW, Mouneimne G, Ros R, Nikkhah M.

Biomaterials. 2016 Mar;81:72-83. doi: 10.1016/j.biomaterials.2015.11.039. Epub 2015 Dec 2.

PMID:
26724455

Supplemental Content

Support Center